Stable aqueous formulations of aflibercept
A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of aflibercept, wherein the formulation is free of organic co-solvent and/or free of buffer; methods for making such a formulation; and methods of using such a formulation.
1. An aqueous formulation comprising:
a. about 30 mg/mL to about 50 mg/mL aflibercept;
b. between about 4% and about 6% sucrose and a stabilizer selected from polymers, salts, human serum albumin, or a combination thereof; and
c. polysorbate, polyethylene glycol (PEG), or a combination thereof, wherein the formulation is free of buffer, the pH of the formulation is about 5.5 to about 7.0, and the formulation is stable at 25° C. for 2 weeks or 40° C. for 1 week.
2. The aqueous formulation of claim 1 , wherein the aqueous formulation comprises a polysorbate.
3. The aqueous formulation of claim 2 , wherein the polysorbate comprises polysorbate 20, polysorbate 80, or a combination thereof.
4. The aqueous formulation of claim 3 , wherein the polysorbate comprises polysorbate 80.
5. The aqueous formulation of claim 1 , wherein the stabilizer comprises a salt.
6. The aqueous formulation of claim 5 , wherein the salt is selected from sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or a combination thereof.
7. The aqueous formulation of claim 1 , wherein the stabilizer comprises a polymer.
8. The aqueous formulation of claim 1 , wherein the polymer comprises a dextrin.
9. The aqueous formulation of claim 8 , wherein the dextrin comprises Captisol, HP-beta-CD, or a combination thereof.
10. The aqueous formulation of claim 1 , wherein the stabilizer comprises human serum albumin.
11. The aqueous formulation of claim 6 , wherein the stabilizer further comprises human serum albumin.
12. The aqueous formulation of claim 1 , wherein the formulation is suitable for ophthalmic administration.